A Phase Ib Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-27

Study Completion Date

2022-06-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Single-center, single-dose, placebo-controlled, open-label trials were used to evaluate the safety and immunogenicity of low-dose adjuvants and low-dose vaccines in the upper arm deltoid muscle intramuscularly in the double negative population. Thirty (PPD-QFT-) healthy adult subjects aged 18-45 were selected and divided into placebo group, low-dose adjuvant group, and low-dose vaccine group. During the test, each subject must not change groups and inoculate drugs. Every two weeks (0-2-4-6-8-10 weeks), alternately inject a dose of placebo or left and right upper arm deltoid muscles. Low-dose adjuvant or low-dose vaccine, a total of 6 doses.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Study of BCG Vaccine for Intradermal Injection

NCT04563273

Tuberculosis

COMPLETED PHASE1

Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents

NCT02378207

Tuberculosis

COMPLETED PHASE1

Immunization With BCG Vaccine to Prevent Tuberculosis Infection

NCT04453293

Tuberculosis Infection

TERMINATED PHASE3

Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults

NCT06062238

Tuberculosis

ACTIVE_NOT_RECRUITING PHASE3

A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6)

NCT00440544

Tuberculosis

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Single-center, single-dose, placebo-controlled, open-label trials were used to evaluate the safety and immunogenicity of low-dose adjuvants and low-dose vaccines in the upper arm deltoid muscle intramuscularly in the double negative population. Thirty (PPD-QFT-) healthy adult subjects aged 18-45 were selected and divided into placebo group, low-dose adjuvant group, and low-dose vaccine group. During the test, each subject must not change groups and inoculate drugs. Every two weeks (0-2-4-6-8-10 weeks), alternately inject a dose of placebo or left and right upper arm deltoid muscles. Low-dose adjuvant or low-dose vaccine, a total of 6 doses.

Collected adverse events within 14 days after each dose of vaccination, non-recruited adverse events within 30 days after the first dose of vaccination, subjects will receive 6 months follow-up after the last dose of vaccination, and study throughout Serious adverse events were recorded during the period. Immunogenicity will be assessed before the first dose, 24 hours after the third dose, before the fourth dose, 24 hours after the sixth dose, 1 month, and 6 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Population I

Population I has 10 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of low dose vaccine.

Group Type EXPERIMENTAL

Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)

Intervention Type BIOLOGICAL

Population I are coxal muscle injection of low dose vaccine.

Population II

Population I has 10 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of low dose adjuvant.

Group Type ACTIVE_COMPARATOR

Low-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)

Intervention Type BIOLOGICAL

Population I are coxal muscle injection of low dose adjuvant.

Population III

Population I has 10 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of placebo.

Group Type PLACEBO_COMPARATOR

Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo

Intervention Type BIOLOGICAL

The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I are coxal muscle injection of placebo.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)

Population I are coxal muscle injection of low dose vaccine.

Intervention Type BIOLOGICAL

Low-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)

Population I are coxal muscle injection of low dose adjuvant.

Intervention Type BIOLOGICAL

Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo

The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I are coxal muscle injection of placebo.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* (1) Age 18-45 years old, body mass index (BMI) = weight (kg) / \[(height (m) × (height (m))\], in the range of 18.0 to 29.9 (including the boundary value);
* (2) I agree to participate in this study and sign an informed consent, and I am willing and able to comply with the requirements of the clinical research protocol;
* (3) Vital signs (reference range of vital signs: systolic blood pressure 90 \~ 140mmHg (including boundary value), diastolic blood pressure 60 \~ 90mmHg (including boundary value), pulse rate 50 \~ 100 beats / min (including boundary value), body temperature (ear Temperature) 35.4 \~ 37.7 ℃ (including the boundary value)), physical examination, clinical laboratory (blood routine, urine routine, blood biochemistry, hepatitis B and AIDS syphilis examination, etc.), electrocardiogram and abdominal B-ultrasound examination, the results showed no abnormalities or abnormalities Non-clinical significance
* (4) Chest X-ray examination showed no abnormalities;
* (5) TB-PPD skin test induration average diameter \<5mm and QFT negative test results;
* (6) No contraindications to vaccination and no history of TB exposure.

Exclusion Criteria

* (1) (Ask) Suffering from acute disease, severe chronic disease, acute episode of chronic disease, acute infectious disease, such as: treatment of malignant tumor, autoimmune disease, progressive atherosclerosis or diabetes with complications, Chronic obstructive pulmonary disease, acute or progressive liver or kidney disease, congestive heart failure, etc. that require oxygen therapy;
* (2) (Ask) those with eczema or other skin diseases;
* (3) (Ask) Those who are known to be allergic to the components of the test drug;
* (4) (Ask) those who have a clear diagnosis of tuberculosis, extrapulmonary tuberculosis or tuberculosis has been cured;
* (5) (Ask) a history of convulsions, epilepsy, encephalopathy and neurological symptoms or signs;
* (6) (Ask) long-term use of antibiotics;
* (7) (Ask) People with known or suspected immune function impairment or abnormality, such as those who received immunosuppressant or immune enhancer treatment within 3 months, received gastrointestinal within 3 months Those who have immunoglobulin preparations or blood products or plasma extracts outside the tract, those with human immunodeficiency virus infection or related diseases;
* (8) (inquiry) those who have no spleen, functional spleen, and spleen or splenectomy caused by any situation
* (9) Examination of one or more clinical significance of hepatitis B surface antigen, hepatitis C virus antibody, anti-human immunodeficiency virus antibody or anti- Treponema pallidum specific antibody;
* (10) Those who have a history of drug abuse or are positive for drug screening;
* (11) Those who donated or lost blood more than 400mL within 3 months before screening;
* (12) those with acute febrile diseases and infectious diseases;
* (13) those who are pregnant, lactating, or have a positive pregnancy test before vaccination, or who cannot guarantee contraception during the study period of this clinical trial;
* (14) Participated in other new drug clinical trials 3 months before screening;
* (15) Any situation that the investigator believes may affect the eva

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes